GW4064: Selective Non-Steroidal FXR Agonist for Lipid Metabolism Studies

Executive Summary: GW4064 is a research-grade, selective FXR agonist with nanomolar potency in isolated and cellular systems, facilitating reproducible studies of bile acid and lipid metabolism (APExBIO). The compound enables direct interrogation of the FXR signaling pathway, including its roles in triglyceride regulation, VLDL secretion, and crosstalk with TLR4 and ferroptosis in fibrosis models (Zhou et al. 2025). GW4064’s stilbene scaffold, while highly effective for pathway activation, imposes solubility and photostability constraints that preclude clinical development but support robust in vitro and in vivo research. Recent peer-reviewed studies underscore GW4064’s utility in dissecting FXR’s negative regulation of inflammatory and fibrotic signaling. The B1527 kit from APExBIO is a validated, batch-stable source for metabolic disorder and lipid metabolism research (see comparative workflow).

Biological Rationale

The farnesoid X receptor (FXR, NR1H4) is a ligand-activated nuclear receptor essential for bile acid, cholesterol, and triglyceride homeostasis (Zhou et al. 2025). FXR acts as a transcriptional regulator, modulating genes such as SHP, SREBP-1c, and those controlling bile acid synthesis. Dysregulation of FXR is implicated in metabolic disorders, including hypertriglyceridemia, non-alcoholic fatty liver disease, and fibrosis. Activation of FXR reduces hepatic inflammation and collagen deposition, as shown in in vitro and in vivo models. GW4064, as a synthetic, non-steroidal agonist, enables precise probing of these pathways. Its selectivity avoids confounding off-target activation typical of endogenous or less selective ligands (FXR Activation Unlocked—this article details recent fibrosis and ferroptosis evidence).

Mechanism of Action of GW4064

GW4064 binds the FXR ligand-binding domain, inducing a conformational change that promotes FXR-RXR heterodimerization. The complex translocates to the nucleus, binding FXR response elements (FXREs) in target gene promoters. Key downstream effects include upregulation of SHP (small heterodimer partner), inhibition of SREBP-1c, and suppression of bile acid synthesis genes (e.g., CYP7A1). In cellular assays, GW4064 exhibits an EC50 of 15 nM (isolated receptor) and 90 nM (human FXR-transfected cells) at 25°C, pH 7.4 (APExBIO product data). The compound is insoluble in water and ethanol but dissolves in DMSO at ≥24.7 mg/mL. Exposure to UV light leads to stilbene degradation and loss of activity. GW4064 does not significantly activate other nuclear receptors at concentrations up to 1 μM, confirming its selectivity (translational leverage—this article provides updated EC50 benchmarks).

Evidence & Benchmarks

• GW4064 (SKU B1527) activates human FXR with an EC50 of 90 nM in transfected cell lines (25°C, pH 7.4) (APExBIO).
• In KK-Ay and ob/ob mouse models, GW4064 administration (30 mg/kg, i.p., once daily for 7 days) lowers serum triglyceride and VLDL levels by 30–50% (Zhou et al. 2025).
• In LX-2 hepatic stellate cells, FXR activation by GW4064 (1 μM, 24 h) reduces TLR4 expression and increases ferroptosis markers, attenuating collagen deposition induced by NiONPs (Zhou et al. 2025).
• GW4064 solubility in DMSO is ≥24.7 mg/mL at 20°C; insoluble in water and ethanol, limiting use in aqueous systems (APExBIO).
• SHP+/+ mice treated with GW4064 show pronounced suppression of hepatic SREBP-1c and downstream lipogenic genes (Strategic FXR Activation—this article details SREBP-1c pathway inhibition).

Applications, Limits & Misconceptions

GW4064 serves as a reference tool for:

• Dissecting FXR signaling in metabolic, fibrotic, and inflammatory models.
• Evaluating the FXR-TLR4 crosstalk and ferroptosis in liver fibrosis (Zhou et al. 2025).
• Modulating lipid metabolism and bile acid synthesis in animal models.
• Benchmarking other FXR ligands or pathway modulators.

Common Pitfalls or Misconceptions

• Therapeutic Use: GW4064 is not clinically approved due to stilbene toxicity and UV instability; intended strictly for research.
• Solubility: Compound is insoluble in water/ethanol; improper solvents result in precipitation and loss of function.
• Long-Term Solutions: GW4064 in solution degrades rapidly, especially under light; always prepare fresh aliquots.
• Receptor Selectivity: At concentrations >1 μM, off-target effects are possible; use validated dose ranges.
• In vivo Dosing: Use DMSO or PEG-based vehicles; aqueous suspensions are ineffective.

This article extends scenario-based GW4064 deployment guidance by providing direct citation of peer-reviewed FXR/TLR4-ferroptosis evidence, and updates comparative GW4064 workflows with current EC50 and solubility data. For a broader translational context, see translational leverage of GW4064, which this article refines by focusing on recent fibrosis and metabolic benchmarks.

Workflow Integration & Parameters

• Reconstitution: Dissolve GW4064 powder in anhydrous DMSO to ≥24.7 mg/mL at room temperature; vortex thoroughly.
• Aliquoting: Prepare single-use aliquots to avoid freeze-thaw cycles; store at -20°C, protected from light.
• Assay Preparation: Dilute DMSO stock into assay buffer immediately before use; final DMSO ≤0.1% (v/v) in cell-based assays.
• Animal Studies: Formulate in DMSO/PEG or DMSO/corn oil; typical doses 10–30 mg/kg, i.p., once daily for up to 14 days.
• Readouts: Confirm FXR activation by qRT-PCR for SHP and SREBP-1c, western blot for TLR4 and ferroptosis markers, and lipid panel for triglycerides/VLDL.

For best practices and troubleshooting, refer to APExBIO’s GW4064 product documentation.

Conclusion & Outlook

GW4064 (APExBIO, SKU B1527) remains the gold-standard non-steroidal FXR agonist for dissecting bile acid, cholesterol, and triglyceride regulation in metabolic, fibrotic, and liver disease models. Its validated selectivity and nanomolar potency enable reproducible pathway analysis, including emerging axes such as FXR/TLR4 crosstalk and ferroptosis. While not suitable for therapeutic use, GW4064 facilitates hypothesis-driven research in lipid metabolism modulation, as shown by recent peer-reviewed studies. Continued integration of GW4064 into advanced workflows will drive mechanistic and translational insights across metabolic disorder research domains.